What is SVRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SVRA?

P/E (TTM) is n/a and 52-week range is $3.35 to $7.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SVRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SVRA?

The company profile lists revenue (TTM) near $260K, net income (TTM) near $-1.11B, EPS (TTM) near $-0.58 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Savara Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Langhorne, Pennsylvania, US, 204.9M shares outstanding, ISIN US8051111016 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Savara Inc

$SVRA

Health Care · Biotechnology

IR Run Scenarios

$4.92

+1.86%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Employees

Website

savarapharma.com/

IPO

2001-06-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)